January 13, 2017 08:05 AM EST

Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk

John Carroll

Editor & Founder

Biogen took a lot of analysts by surprise recently when the big biotech announced that its breakthrough drug for spinal muscular atrophy would be priced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk

John Carroll

Editor & Founder

Sign up to read this article for free.

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Is Spin­raza worth $750K? Bio­gen says yes, spelling out re­duced death risk

John Carroll

Editor & Founder

Sign up to read this article for free.

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks